Revel Pharmaceuticals is a biotechnology commercializing therapeutic enzymes to degrade age associated molecule damage. Working from research developed at a Yale laboratory with the assistance of SENS Research Foundation, Revel Pharmaceuticals is developing enzymes that break glucosepane. Glucosepane is an advanced glycation end-product (AGE) that binds to collagen, causing it to stiffen, which leads to hardening of the arteries, high blood pressure, and kidney and brain disease. The human body has few or no effective methods of getting rid of this harmful substance, causing it to accumulate with age, and if Revel’s enzymatic approach is proven to be successful in clinical trials, it will prove to be a significant milestone for rejuvenation biotechnology as a whole.